However, it was reported that tumor types including HER2-expressing or HER2-amplified salivary gland cancer, biliary tract cancer, and endometrial cancer, and HER2-mutant nonamplified breast cancer had a median progression-free survival of 11.0 months (95% CI, 2.8-Not evaluated) [79]. Here, ERBB2 is linked to biliary tract cancer.